Micromet developed highly potent bi-specific antibody-based drugs for the treatment of cancer, autoimmune and inflammatory diseases. Micromet completed a reverse takeover of CancerVax in May 2006 and was acquired by Amgen for $1.2 billion in March 2012.

Location Munich, Germany